Launching an initial public offering can be risky in an election year, but considering the generally strong performance of biopharmaceutical companies that went public in 2019, the consensus at the recent J.P. Morgan Healthcare Conference and concurrent Biotech Showcase in San Francisco was that the first half of 2020 will be busy for drug developer IPOs before slowing in the second half due to uncertainty over the US presidential election results.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?